Table 1.

Clinical characteristics of patients from the extended cohort and the trial EURO-LB02

Targeted sequence (n = 122) n%T-LBL cohort from EURO-LB 02 (n = 279) n%P (targeted cohort vs T-LBL cohort)
Total patients 122  279   
Sex     .5 
 Male 90 73.8 214 76.7  
 Female 32 26.2 65 23.3  
Age, y     .6 
 <10 64 52.5 154 55.2  
 10-14 41 33.6 95 34.1  
 ≥15 17 13.9 30 10.8  
Stage     .4 
 II 2 1.8 9 3.9  
 III 84 77.1 164 70.7  
 IV 23 21.1 59 25.4  
Bone marrow involvement     .9 
 No 84 80.8 227 81.4  
 Yes 20 19.2 52 18.6  
Mediastinal tumor     .2 
 No 12 9.8 18 6.5  
 Yes 110 90.2 261 93.5  
CNS involvement     .1 
 No 116 98.3 266 95.3  
 Yes 2 1.7 13 4.7  
General condition     .03 
 Good 92 80.7 247 88.8  
 Poor (Karnofsky ≤20%) 22 19.3 31 11.2  
Status      
 Relapse 20 16.4 34 12.2  
Targeted sequence (n = 122) n%T-LBL cohort from EURO-LB 02 (n = 279) n%P (targeted cohort vs T-LBL cohort)
Total patients 122  279   
Sex     .5 
 Male 90 73.8 214 76.7  
 Female 32 26.2 65 23.3  
Age, y     .6 
 <10 64 52.5 154 55.2  
 10-14 41 33.6 95 34.1  
 ≥15 17 13.9 30 10.8  
Stage     .4 
 II 2 1.8 9 3.9  
 III 84 77.1 164 70.7  
 IV 23 21.1 59 25.4  
Bone marrow involvement     .9 
 No 84 80.8 227 81.4  
 Yes 20 19.2 52 18.6  
Mediastinal tumor     .2 
 No 12 9.8 18 6.5  
 Yes 110 90.2 261 93.5  
CNS involvement     .1 
 No 116 98.3 266 95.3  
 Yes 2 1.7 13 4.7  
General condition     .03 
 Good 92 80.7 247 88.8  
 Poor (Karnofsky ≤20%) 22 19.3 31 11.2  
Status      
 Relapse 20 16.4 34 12.2  

Characteristics of the extended cohort (targeted sequencing) and of the EURO-LB02 trial as the representative reference cohort. All cases for which the corresponding clinical data are available in the NHL-BFM databases are included.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal